Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis

Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Method Consecutive patients were enrolled between Ma...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of rheumatic diseases Vol. 24; no. 6; pp. 781 - 788
Main Authors Sammel, Anthony M., Xue, Meilang, Karsten, Elisabeth, Little, Christopher B., Smith, Susan, Nguyen, Katherine, Laurent, Rodger
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.06.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Method Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra‐cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5‐plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon‐γ (high‐sensitivity 3‐plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). Results For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy‐positive GCA and a further 9 had a clinical diagnosis of biopsy‐negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy‐positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. Conclusion This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA.
AbstractList Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra-cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5-plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon-γ (high-sensitivity 3-plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy-positive GCA and a further 9 had a clinical diagnosis of biopsy-negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy-positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA.
Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. Method Consecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra‐cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5‐plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon‐γ (high‐sensitivity 3‐plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). Results For the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy‐positive GCA and a further 9 had a clinical diagnosis of biopsy‐negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy‐positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. Conclusion This study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA.
AIMDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients. METHODConsecutive patients were enrolled between May 2016 and December 2017. Serum was collected within 72 hours of commencing corticosteroids and at 6 months. It was analyzed for levels of intra-cellular adhesion molecule 1, vascular endothelial growth factor (VEGF), pentraxin 3, von Willebrand factor and procalcitonin (5-plex R&D Systems multiplex assay) and interleukin (IL)6, IL12 and interferon-γ (high-sensitivity 3-plex ProcartaPlex multiplex assay). A GCA specific positron emission tomography / computed tomography (PET/CT) scan was performed at enrolment with uptake in each vascular territory graded and summed to derive a total vascular score (TVS). RESULTSFor the 63 patients enrolled, 12 (19%) had a final diagnosis of biopsy-positive GCA and a further 9 had a clinical diagnosis of biopsy-negative GCA. None of the 8 biomarkers was significantly higher in GCA patients compared with those with alternative diagnoses, or demonstrated a positive correlation with the PET/CT TVS. This was in contrast to the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) which were higher in the biopsy-positive GCA cohort (P < .04) and showed weak positive correlations with the TVS (correlation coefficient 0.34, P < .01). Procalcitonin did not distinguish between GCA and infection. Concentrations of CRP, ESR, VEGF and pentraxin 3 decreased between diagnosis and 6 months in GCA patients. CONCLUSIONThis study did not identify new serological biomarkers to assist in diagnosing or assessing the vasculitis burden in GCA.
Author Nguyen, Katherine
Laurent, Rodger
Sammel, Anthony M.
Karsten, Elisabeth
Smith, Susan
Xue, Meilang
Little, Christopher B.
Author_xml – sequence: 1
  givenname: Anthony M.
  orcidid: 0000-0003-3641-796X
  surname: Sammel
  fullname: Sammel, Anthony M.
  email: anthony.sammel@health.nsw.gov.au
  organization: University of New South Wales
– sequence: 2
  givenname: Meilang
  surname: Xue
  fullname: Xue, Meilang
  organization: Kolling Institute, Faculty of Medicine and Health, The University of Sydney
– sequence: 3
  givenname: Elisabeth
  surname: Karsten
  fullname: Karsten, Elisabeth
  organization: Sangui Bio Pty Ltd. Kolling Institute
– sequence: 4
  givenname: Christopher B.
  surname: Little
  fullname: Little, Christopher B.
  organization: Kolling Institute, Faculty of Medicine and Health, University of Sydney
– sequence: 5
  givenname: Susan
  surname: Smith
  fullname: Smith, Susan
  organization: Kolling Institute, Faculty of Medicine and Health, University of Sydney
– sequence: 6
  givenname: Katherine
  surname: Nguyen
  fullname: Nguyen, Katherine
  organization: Royal North Shore Hospital
– sequence: 7
  givenname: Rodger
  surname: Laurent
  fullname: Laurent, Rodger
  organization: University of Sydney
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33847438$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtrGzEURkVIyHvdXRF0042T0eg1XpqQNgVDskggO6HR3HHkypIraWz876uJUy-6ibTQg3MPl-9eoGMfPCD0hVQ3pKxbIrmYkIa_3hBW3kfo_PBzfLgzcoYuUlpWlSBUyFN0RmnDJKPNOVrO7cpm6PCQrbN5h0OPfdiAwwlicGFhjXa4tWGl42-ICVuP1zpb8DlhD1u3w2lIazCjo9S-6Y31C7yw2mdswDmsY4Zos01X6KTXLsH1x3mJXn7cP989TOaPP3_dzeYTw6gkEyFl1TZGl801qzpeM8ME7UTXGkl0T9mUNNowrmtOpdS1YD20wOu2Mz3rKL1E3_fedQx_BkhZrWwaW9EewpBUzUlNGZ2SEf32H7oMQ_SlOzXKhWAlsELd7ikTQ0oRerWOtuSxU6RS4xjUGLQaQ1fvYygVXz-8Q7uC7sD_y70AfA9srYPdZz41e5rvxX8BtpKVLA
CitedBy_id crossref_primary_10_1016_j_cca_2023_117592
crossref_primary_10_1080_03009742_2022_2047311
crossref_primary_10_3389_fimmu_2022_1066916
crossref_primary_10_1055_a_1942_6311
Cites_doi 10.1002/art.1780330810
10.1136/annrheumdis-2019-215697
10.1136/annrheumdis-2013-204572
10.1093/rheumatology/ker163
10.1007/s40674-016-0043-x
10.1097/ICU.0000000000000528
10.1136/rmdopen-2016-000353
10.1080/08916930903002495
10.1016/S1473-3099(17)30592-3
10.1002/art.1780360913
10.1186/1471-2172-10-52
10.1002/art.22368
10.1038/nrrheum.2013.161
10.1136/ard.53.8.521
10.1002/art.1780270912
10.1002/art.40864
10.1056/NEJMoa1613849
10.1097/01.md.0000180043.19285.54
10.1136/ard.55.12.927
10.1136/ard.50.5.316
10.1161/CIRCULATIONAHA.109.872903
10.1038/nrneph.2017.51
10.1136/annrheumdis-2018-214704
10.1016/j.autrev.2017.05.014
10.1136/ard.58.3.189
10.1097/01.md.0000180042.42156.d1
10.1136/annrheumdis-2019-215672
10.1016/j.semarthrit.2011.10.005
10.1002/art.33411
10.1186/s13075-016-1184-x
10.1093/rheumatology/keu526
10.1111/1756-185X.13702
10.1002/acr.20043
10.1001/jama.287.1.92
10.1093/rheumatology/keq039a
10.1186/s12916-017-0795-7
ContentType Journal Article
Copyright 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
International Journal of Rheumatic Diseases © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd
Copyright_xml – notice: 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
– notice: International Journal of Rheumatic Diseases © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd
DBID NPM
AAYXX
CITATION
7QP
7T5
H94
7X8
DOI 10.1111/1756-185X.14111
DatabaseName PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-185X
EndPage 788
ExternalDocumentID 10_1111_1756_185X_14111
33847438
APL14111
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OC
29J
31~
33P
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
HF~
HGLYW
HVGLF
HZI
HZ~
IX1
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
~IA
~WT
NPM
AAMNL
AAYXX
ACRPL
ACYXJ
CITATION
7QP
7T5
H94
7X8
ID FETCH-LOGICAL-c4371-6770b8cacac5a40d524c463d6dbc71af34918ac45a25377a264febe52bdcf4d33
IEDL.DBID DR2
ISSN 1756-1841
IngestDate Wed Dec 04 06:47:03 EST 2024
Tue Nov 19 05:20:58 EST 2024
Fri Dec 06 04:26:55 EST 2024
Sat Sep 28 08:23:29 EDT 2024
Sat Aug 24 01:03:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords giant cell arteritis
vasculitis
interleukin-6
enzyme-linked immunosorbent assay
immunoassay
Language English
License 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4371-6770b8cacac5a40d524c463d6dbc71af34918ac45a25377a264febe52bdcf4d33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3641-796X
PMID 33847438
PQID 2537664136
PQPubID 1086355
PageCount 8
ParticipantIDs proquest_miscellaneous_2512343913
proquest_journals_2537664136
crossref_primary_10_1111_1756_185X_14111
pubmed_primary_33847438
wiley_primary_10_1111_1756_185X_14111_APL14111
PublicationCentury 2000
PublicationDate June 2021
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: June 2021
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Richmond
PublicationTitle International journal of rheumatic diseases
PublicationTitleAlternate Int J Rheum Dis
PublicationYear 2021
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2018; 29
2019; 71
1990; 33
2017; 3
2009; 42
1984; 27
2019; 78
1991; 50
2015; 54
2005; 84
2010; 121
2020; 79
2016; 18
2017; 377
2007; 56
2010; 62
2013; 9
1996; 55
1993; 36
2018; 18
2010; 49
2016; 2
2009; 10
2017; 15
2019; 22
2017; 16
2002; 287
2017; 13
2011; 50
2008; 28
1999; 58
2008; 26
2014; 73
2012; 64
2012; 41
1994; 53
e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_16_1
e_1_2_6_37_1
Maruotti N (e_1_2_6_9_1) 2008; 26
e_1_2_6_21_1
e_1_2_6_20_1
Remahl AI (e_1_2_6_22_1) 2008; 28
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_29_1
e_1_2_6_28_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 55
  start-page: 927
  issue: 12
  year: 1996
  end-page: 930
  article-title: Von Willebrand factor in the outcome of temporal arteritis
  publication-title: Ann Rheum Dis
– volume: 62
  start-page: 835
  issue: 6
  year: 2010
  end-page: 841
  article-title: Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin‐6) in the long‐term followup of patients with giant cell arteritis
  publication-title: Arthritis Care Res
– volume: 27
  start-page: 1046
  issue: 9
  year: 1984
  end-page: 1049
  article-title: Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis
  publication-title: Arthritis Rheum
– volume: 29
  start-page: 520
  issue: 6
  year: 2018
  end-page: 527
  article-title: Update on giant cell arteritis
  publication-title: Curr Opin Ophthalmol
– volume: 58
  start-page: 189
  issue: 3
  year: 1999
  end-page: 192
  article-title: Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule‐1 (sICAM‐1) concentrations and disease activity
  publication-title: Ann Rheum Dis
– volume: 26
  start-page: 476
  issue: 3
  year: 2008
  end-page: 483
  article-title: Angiogenesis in vasculitides
  publication-title: Clin Exp Rheumatol
– volume: 121
  start-page: 906
  issue: 7
  year: 2010
  end-page: 915
  article-title: Th17 and Th1 T‐cell responses in giant cell arteritis
  publication-title: Circulation
– volume: 15
  start-page: 15
  issue: 1
  year: 2017
  article-title: Procalcitonin‐guided diagnosis and antibiotic stewardship revisited
  publication-title: BMC Med
– volume: 36
  start-page: 1286
  issue: 9
  year: 1993
  end-page: 1294
  article-title: Correlation of interleukin‐6 production and disease activity in polymyalgia rheumatica and giant cell arteritis
  publication-title: Arthritis Rheum
– volume: 49
  start-page: 1594
  issue: 8
  year: 2010
  end-page: 1597
  article-title: BSR and BHPR guidelines for the management of giant cell arteritis
  publication-title: Rheumatology (Oxford)
– volume: 78
  start-page: 1012
  issue: 7
  year: 2019
  end-page: 1014
  article-title: Serial IL‐6 measurements in patients with tocilizumab‐treated large‐vessel vasculitis detect infections and may predict early relapses
  publication-title: Ann Rheum Dis
– volume: 53
  start-page: 521
  issue: 8
  year: 1994
  end-page: 524
  article-title: Circadian rhythm of serum interleukin‐6 in rheumatoid arthritis
  publication-title: Ann Rheum Dis
– volume: 84
  start-page: 269
  issue: 5
  year: 2005
  end-page: 276
  article-title: Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients
  publication-title: Medicine
– volume: 10
  start-page: 52
  year: 2009
  article-title: Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays
  publication-title: BMC Immunol
– volume: 18
  start-page: 95
  issue: 1
  year: 2018
  end-page: 107
  article-title: Effect of procalcitonin‐guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta‐analysis
  publication-title: Lancet Infect Dis
– volume: 41
  start-page: 866
  issue: 6
  year: 2012
  end-page: 871
  article-title: Utility of erythrocyte sedimentation rate and C‐reactive protein for the diagnosis of giant cell arteritis
  publication-title: Semin Arthritis Rheum
– volume: 50
  start-page: 316
  issue: 5
  year: 1991
  end-page: 320
  article-title: von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis
  publication-title: Ann Rheum Dis
– volume: 79
  start-page: 19
  issue: 1
  year: 2020
  end-page: 30
  article-title: 2018 Update of the EULAR recommendations for the management of large vessel vasculitis
  publication-title: Ann Rheum Dis
– volume: 84
  start-page: 277
  issue: 5
  year: 2005
  end-page: 290
  article-title: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients
  publication-title: Medicine
– volume: 33
  start-page: 1122
  issue: 8
  year: 1990
  end-page: 1128
  article-title: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
  publication-title: Arthritis Rheum
– volume: 13
  start-page: 368
  issue: 6
  year: 2017
  end-page: 380
  article-title: The immunology of atherosclerosis
  publication-title: Nat Rev Nephrol
– volume: 2
  start-page: 126
  issue: 2
  year: 2016
  end-page: 137
  article-title: Giant cell arteritis: from pathogenesis to therapeutic management
  publication-title: Curr Treat Options Rheumatol
– volume: 18
  start-page: 283
  issue: 1
  year: 2016
  article-title: Vascular endothelial growth factor levels and rheumatic diseases of the elderly
  publication-title: Arthritis Res Ther
– volume: 64
  start-page: 854
  issue: 3
  year: 2012
  end-page: 865
  article-title: Selective up‐regulation of the soluble pattern‐recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia
  publication-title: Arthritis Rheum
– volume: 28
  start-page: 157
  issue: 2
  year: 2008
  end-page: 163
  article-title: Comparison of soluble ICAM‐1, VCAM‐1 and E‐selectin levels in patients with episodic cluster headache and giant cell arteritis
  publication-title: Cephalalgia
– volume: 54
  start-page: 1397
  issue: 8
  year: 2015
  end-page: 1402
  article-title: Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica
  publication-title: Rheumatology (Oxford)
– volume: 56
  start-page: 399
  issue: 2
  year: 2007
  end-page: 408
  article-title: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management
  publication-title: Arthritis Rheum
– volume: 16
  start-page: 833
  issue: 8
  year: 2017
  end-page: 844
  article-title: Recent advances in our understanding of giant cell arteritis pathogenesis
  publication-title: Autoimmun Rev
– volume: 3
  issue: 1
  year: 2017
  article-title: Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
  publication-title: RMD open
– volume: 287
  start-page: 92
  issue: 1
  year: 2002
  end-page: 101
  article-title: Does this patient have temporal arteritis?
  publication-title: JAMA
– volume: 50
  start-page: 2061
  issue: 11
  year: 2011
  end-page: 2070
  article-title: Tissue and serum markers of inflammation during the follow‐up of patients with giant‐cell arteritis–a prospective longitudinal study
  publication-title: Rheumatology (Oxford)
– volume: 22
  start-page: 1900
  issue: 10
  year: 2019
  end-page: 1904
  article-title: Circulating interleukin‐6 as a biomarker in a randomized controlled trial of modified‐release prednisone vs immediate‐release prednisolone, in newly diagnosed patients with giant cell arteritis
  publication-title: Int J Rheum Dis
– volume: 79
  start-page: e102
  issue: 8
  year: 2020
  article-title: Analysis of IL‐6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone
  publication-title: Ann Rheum Dis
– volume: 71
  start-page: 1319
  issue: 8
  year: 2019
  end-page: 1328
  article-title: Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double‐blind, cross‐sectional study
  publication-title: Arthritis Rheum
– volume: 42
  start-page: 596
  issue: 7
  year: 2009
  end-page: 604
  article-title: Vascular damage in giant cell arteritis
  publication-title: Autoimmunity
– volume: 73
  start-page: 1388
  issue: 7
  year: 2014
  end-page: 1392
  article-title: Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy‐proven giant cell arteritis: a prospective, case‐control study
  publication-title: Ann Rheum Dis
– volume: 9
  start-page: 731
  issue: 12
  year: 2013
  end-page: 740
  article-title: Immune mechanisms in medium and large‐vessel vasculitis
  publication-title: Nat Rev Rheumatol
– volume: 377
  start-page: 317
  issue: 4
  year: 2017
  end-page: 328
  article-title: Trial of tocilizumab in giant‐cell arteritis
  publication-title: N Engl J Med
– ident: e_1_2_6_19_1
  doi: 10.1002/art.1780330810
– ident: e_1_2_6_34_1
  doi: 10.1136/annrheumdis-2019-215697
– ident: e_1_2_6_29_1
  doi: 10.1136/annrheumdis-2013-204572
– ident: e_1_2_6_14_1
  doi: 10.1093/rheumatology/ker163
– ident: e_1_2_6_6_1
  doi: 10.1007/s40674-016-0043-x
– ident: e_1_2_6_8_1
  doi: 10.1097/ICU.0000000000000528
– ident: e_1_2_6_10_1
  doi: 10.1136/rmdopen-2016-000353
– ident: e_1_2_6_27_1
  doi: 10.1080/08916930903002495
– ident: e_1_2_6_36_1
  doi: 10.1016/S1473-3099(17)30592-3
– ident: e_1_2_6_32_1
  doi: 10.1002/art.1780360913
– ident: e_1_2_6_37_1
  doi: 10.1186/1471-2172-10-52
– volume: 28
  start-page: 157
  issue: 2
  year: 2008
  ident: e_1_2_6_22_1
  article-title: Comparison of soluble ICAM‐1, VCAM‐1 and E‐selectin levels in patients with episodic cluster headache and giant cell arteritis
  publication-title: Cephalalgia
  contributor:
    fullname: Remahl AI
– ident: e_1_2_6_38_1
  doi: 10.1002/art.22368
– ident: e_1_2_6_7_1
  doi: 10.1038/nrrheum.2013.161
– ident: e_1_2_6_39_1
  doi: 10.1136/ard.53.8.521
– ident: e_1_2_6_13_1
  doi: 10.1002/art.1780270912
– ident: e_1_2_6_18_1
  doi: 10.1002/art.40864
– ident: e_1_2_6_28_1
  doi: 10.1056/NEJMoa1613849
– ident: e_1_2_6_5_1
  doi: 10.1097/01.md.0000180043.19285.54
– ident: e_1_2_6_11_1
  doi: 10.1136/ard.55.12.927
– ident: e_1_2_6_12_1
  doi: 10.1136/ard.50.5.316
– ident: e_1_2_6_24_1
  doi: 10.1161/CIRCULATIONAHA.109.872903
– volume: 26
  start-page: 476
  issue: 3
  year: 2008
  ident: e_1_2_6_9_1
  article-title: Angiogenesis in vasculitides
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Maruotti N
– ident: e_1_2_6_25_1
  doi: 10.1038/nrneph.2017.51
– ident: e_1_2_6_33_1
  doi: 10.1136/annrheumdis-2018-214704
– ident: e_1_2_6_17_1
  doi: 10.1016/j.autrev.2017.05.014
– ident: e_1_2_6_23_1
  doi: 10.1136/ard.58.3.189
– ident: e_1_2_6_3_1
  doi: 10.1097/01.md.0000180042.42156.d1
– ident: e_1_2_6_21_1
  doi: 10.1136/annrheumdis-2019-215672
– ident: e_1_2_6_4_1
  doi: 10.1016/j.semarthrit.2011.10.005
– ident: e_1_2_6_15_1
  doi: 10.1002/art.33411
– ident: e_1_2_6_26_1
  doi: 10.1186/s13075-016-1184-x
– ident: e_1_2_6_30_1
  doi: 10.1093/rheumatology/keu526
– ident: e_1_2_6_16_1
  doi: 10.1111/1756-185X.13702
– ident: e_1_2_6_31_1
  doi: 10.1002/acr.20043
– ident: e_1_2_6_2_1
  doi: 10.1001/jama.287.1.92
– ident: e_1_2_6_20_1
  doi: 10.1093/rheumatology/keq039a
– ident: e_1_2_6_35_1
  doi: 10.1186/s12916-017-0795-7
SSID ssj0061367
Score 2.2910128
Snippet Aim Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed...
Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the...
AimDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed...
AIMDiagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 781
SubjectTerms Arteritis
Biomarkers
Biopsy
Computed tomography
Corticosteroids
Diagnosis
enzyme‐linked immunosorbent assay
Erythrocyte sedimentation rate
giant cell arteritis
immunoassay
Interferon
Interleukin 1
Interleukin 12
interleukin‐6
Pentraxins
Positron emission tomography
Procalcitonin
Serology
Vascular endothelial growth factor
Vasculitis
Von Willebrand factor
Title Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1756-185X.14111
https://www.ncbi.nlm.nih.gov/pubmed/33847438
https://www.proquest.com/docview/2537664136
https://search.proquest.com/docview/2512343913
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8UwEB7Eg3hxX-pGBA9eKk2TJu1RXBBREVHwVpK0FRf6xL4n6K93Jm0fLgcR6SXQpM0yk_mSzHwB2OFcOadEFFqlZShVlIZpmqFeFTyu0iypYr-VfX6hTm7k6W3SexNSLEzLDzHecCPN8PM1KbixzSclR7unQrQ2t6js3Ef3cqHJqe_wakwgpYiQzIdE-rySd-Q-5MvzrfxXu_QDbH7Frt74HM-C7avd-pw87o2Gds-9f2N0_Fe75mCmg6Zsv5WleZgo6wWYOu8O3xfhoQuGYiirBN7ZoGL14LV8YijG_RzKKJ6fXH5eGnZfs462tWGI3p_eWDPykZ34DSxL_AD1HbtDAR0yOkBg3r-USJaW4Ob46PrgJOyuagidFJqHSuvIps7gkxgZFUksnVSCbqtymptKyIynxsnExInQ2iAMq1B8ktgWrpKFEMswWQ_qchWYtBYnPhNlIq0k4hVLt4NEujCyitHOZgHs9gOVP7eMHHm_kqG-y6nvct93AWz0A5l3qtnkVAGl0HarALbHr1GpqKGmLgcjyoMGnWKSRQArrQCM_4VreomwKw2gHcbfKpHvX575xNpfC6zDdEweNH7PZwMmhy-jchMh0NBueSn_ABUH-bA
link.rule.ids 314,780,784,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB5EQX3xPuoZwQdfKk2Tpu2jeLDqrogo7FtJ03bxoCvurqC_3pm0XTweRKQvhSZpjpnMl2TmC8A-58oYJTw3VaF0pfIiN4pi1KuM-0UUB4Vvt7I7V6p1Jy-6QfdTLEzFDzHecCPNsPM1KThtSH_ScjR8ykVz00Vt5xTeO4VKz8mt6-RmTCGliJLMBkXaxJLX9D7kzfOtgK-W6Qfc_Iperfk5mwfTVLzyOnk8HA3TQ_P-jdPxfy1bgLkanbKjSpwWYSIvl2C6U5-_L8NDHQ_FUFwJv7N-wcr-a_7EUJKbaZRRSD95_bwM2H3JaubWAUMA__TGBiMb3IllYF6iCCh7rIcyOmR0hsCsiynxLK3A3dnp7XHLrW9rcI0UIXdVGHppZDQ-gZZeFvjSSCXowioTcl0IGfNIGxloPxBhqBGJFShBgZ9mppCZEKswWfbLfB2YTFOc-7QXi6iQCFlSuiDECzMtCx9NbezAQTNSyXNFypE0ixnqu4T6LrF958BWM5JJrZ2DhCqgFJpv5cDe-DPqFTVUl3l_RGnQplNYsnBgrZKA8b9wWS8ReUUOVOP4WyWSo-u2fdn4a4ZdmGnddtpJ-_zqchNmfXKosVtAWzA5fBnl24iIhumOFfkPzvP90Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8UwEB5EQby4L3WN4MFLpW3StD2K-nBHRMFbSdLm4UKf-N4T9Nc7k7YPl4OI9FJokmaZyXxJZr4A7IShNEbywNcyEb6QQeqnaYZ6VYSRTbPYRm4r--JSHt-K07u49SakWJiaH2K04Uaa4eZrUvDnwn5ScrR70kdrc4fKHlJ074SQUUb0-YfXIwYpSYxkLibSJRZhw-5DzjzfCvhqmH6gza_g1Vmfzgzott6108nj3nCg98z7N0rHfzVsFqYbbMr2a2Gag7GymofJi-b0fQEemmgohsJK6J31LKt6r-UTQzluJ1FGAf3k8_PSZ_cVa3hb-wzh-9Mb6w9daCeWgXmJIKDqsi5K6IDRCQJzDqbEsrQIt52jm4Njv7mrwTeCJ6EvkyTQqVH4xEoERRwJIySn66pMEirLRRamyohYRTFPEoU4zKL8xJEujBUF50swXvWqcgWY0BpnPhVkPLUCAYum60GCpFDCRmhoMw9224HKn2tKjrxdylDf5dR3ues7D9bbgcwb3eznVAEp0XhLD7ZHn1GrqKGqKntDSoMWnYKSuQfLtQCM_oWLeoG4K_WgHsbfKpHvX527l9W_ZtiCyavDTn5-cnm2BlMRedO4_Z91GB-8DMsNhEMDvekE_gPMNvyA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Limited+utility+of+novel+serological+biomarkers+in+patients+newly+suspected+of+having+giant+cell+arteritis&rft.jtitle=International+journal+of+rheumatic+diseases&rft.au=Sammel%2C+Anthony+M.&rft.au=Xue%2C+Meilang&rft.au=Karsten%2C+Elisabeth&rft.au=Little%2C+Christopher+B.&rft.date=2021-06-01&rft.issn=1756-1841&rft.eissn=1756-185X&rft.volume=24&rft.issue=6&rft.spage=781&rft.epage=788&rft_id=info:doi/10.1111%2F1756-185X.14111&rft.externalDBID=10.1111%252F1756-185X.14111&rft.externalDocID=APL14111
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-1841&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-1841&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-1841&client=summon